Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 16/20 | 0.53 |
| ▸ | ACVR1 | Q04771 | 16/20 | 0.53 |
| ▸ | BMPR1B | O00238 | 15/20 | 0.53 |
| ▸ | BMPR1A | P36894 | 15/20 | 0.53 |
| ▸ | TGFBR1 | P36897 | 11/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL777270 | 0.88 | ACVRL1 (0.56) | ACVRL1ACVR1BMPR1BBMPR1ATGFBR1 | |
| SCHEMBL14780347 | 0.82 | CYP11B1 (0.57) | CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL777530 | 0.77 | ACVRL1 (0.57) | ACVRL1ACVR1BMPR1BBMPR1ATGFBR1 | |
| SCHEMBL1877985 | 0.77 | ACVRL1 (0.65) | ACVRL1ACVR1BMPR1BBMPR1ATGFBR1 | |
| SCHEMBL768711 | 0.73 | ACVRL1 (0.56) | ACVRL1ACVR1BMPR1BBMPR1ATGFBR1 | |
| SCHEMBL746915 | 0.71 | CYP11B1 (0.80) | ACVRL1ACVR1BMPR1BBMPR1ATGFBR1 | |
| SCHEMBL10234020 | 0.71 | KCNJ1 (0.49) | CYP11B1CYP11B2PRMT6 | |
| SCHEMBL21535172 | 0.70 | CYP11B1 (0.55) | CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL31260061 | 0.70 | CYP11B1 (0.55) | CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL14789761 | 0.70 | CYP11B1 (0.60) | CYP1A2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778972-B2 | 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | CYP11B1, HSD11B1, CYP11B2 | ACVRL1 950/4885ACVR1 522/4885BMPR1B 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.